Taiwan Food and Drug Administration (TFDA) โ Medical Device Regulator
The Taiwan Food and Drug Administration (TFDA), under the Ministry of Health and Welfare (MOHW), regulates medical devices under the Medical Devices Act (้ซ็ๅจๆ็ฎก็ๆณ) effective May 1, 2021. All devices must be listed in the Taiwan Medical Devices Listing before commercial sale.
Taiwan classifies devices into four classes (IโIV) based on risk. Class I requires notification registration, while Class IIโIV require full product registration with technical dossiers. Foreign manufacturers must appoint a locally registered Taiwan agent to act as the local representative for all TFDA submissions.
A key advantage for devices already approved by CE (MDR/IVDR), US FDA (510(k)/PMA), or PMDA (Japan) is the Abridged Pathway โ expedited review based on reference approvals, reducing review time and documentation requirements by 30โ50% for eligible products.
- All devices must be listed in the Taiwan Medical Devices Listing before market placement
- Licensed Taiwan Agent required โ foreign manufacturers cannot register directly
- Abridged pathway available for CE/FDA/PMDA-approved devices (30โ50% faster)
- Post-market surveillance, adverse event reporting, and variation filing required
- GMP compliance audit may be required for Class IIIโIV devices
TFDA Review Timelines by Device Class
Target review times from submission acceptance โ excluding deficiency response periods.
Integrated Services for Taiwan TFDA Registration
TFDA Device Registration
End-to-end TFDA submission management for Class IโIV โ dossier preparation, abridged pathway eligibility assessment, portal submission, deficiency response, and approval tracking. IVD and SaMD registration included.
Licensed Taiwan Agent
JNPMEDI APAC acts as your licensed Taiwan agent โ the locally registered entity required by TFDA to submit and hold device registrations on behalf of foreign manufacturers. Full variation management and renewal tracking included.
Post-Market & NHI Strategy
Post-approval compliance including TFDA adverse event reporting, GMP support, and registration renewal โ plus strategic guidance on Taiwan's National Health Insurance (NHI) listing, the critical step for actual hospital channel access.
Why JNPMEDI APAC for Taiwan TFDA Registration
Taiwan's Abridged Pathway can reduce review time by 30โ50% for devices with CE, FDA, or PMDA approvals. Our team identifies eligibility early, prepares the reference documentation package, and handles TFDA technical queries โ reducing timeline risk on this route.
Taiwan is a natural complement to Japan and Korea registrations. Dossier components, clinical evidence, and technical files frequently overlap across PMDA, MFDS, and TFDA submissions. We coordinate all three markets to maximize document reuse and minimize total registration cost.
Taiwan's National Health Insurance (NHI) system covers 99% of the population and heavily influences device uptake. JNPMEDI APAC advises on NHI listing strategy โ the post-registration step that determines actual commercial access in Taiwan's hospital and clinic channel.
Taiwan TFDA Registration โ FAQ
Yes. TFDA requires a locally licensed Taiwan agent to submit and hold medical device registrations. Foreign manufacturers cannot register directly. JNPMEDI APAC serves as your Taiwan agent of record, handling all TFDA submissions, variation filings, and post-market obligations โ eliminating the need for a local subsidiary at market entry.
The Abridged Pathway allows expedited registration for devices with existing CE (MDR/IVDR), US FDA (510(k)/PMA), or PMDA approvals. Eligible devices undergo streamlined review โ typically 60โ90 days versus 180โ270 days for full review. Eligibility depends on device classification, intended use equivalence, and completeness of reference approval documentation. We conduct pathway eligibility assessment as part of our registration planning process.
The Medical Devices Act (effective May 1, 2021) established a dedicated regulatory framework, separating medical devices from the pharmaceutical regime they were previously governed under. It introduced formal four-tier classification, mandatory UDI requirements, strengthened post-market surveillance, and a structured GMP inspection program aligned with international standards.
Yes. JNPMEDI APAC coordinates simultaneous TFDA, PMDA, and MFDS submissions. Technical files, clinical evidence, and performance data overlap significantly across these three regulators โ substantially reducing total preparation cost and timeline for Northeast Asia market entry.